The burden of chronic disease, multimorbidity, and polypharmacy in adults with Down syndrome.
Down syndrome
complexity
intellectual disability
multimorbidity
polypharmacy
Journal
American journal of medical genetics. Part A
ISSN: 1552-4833
Titre abrégé: Am J Med Genet A
Pays: United States
ID NLM: 101235741
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
17
12
2019
revised:
02
03
2020
accepted:
04
05
2020
pubmed:
26
5
2020
medline:
29
4
2021
entrez:
26
5
2020
Statut:
ppublish
Résumé
Data on clinical characteristics of adults with Down syndrome (DS) are limited and the clinical phenotype of these persons is poorly described. This study aimed to describe the occurrence of chronic diseases and pattern of medication use in a population of adults with DS. Participants were 421 community dwelling adults with DS, aged 18 years or older. Individuals were assessed through a standardized clinical protocol. Multimorbidity was defined as the occurrence of two or more chronic conditions and polypharmacy as the concomitant use of five or more medications. The mean age of study participants was 38.3 ± 12.8 years and 214 (51%) were women. Three hundred and seventy-four participants (88.8%) presented with multimorbidity. The most prevalent condition was visual impairment (72.9%), followed by thyroid disease (50.1%) and hearing impairment (26.8%). Chronic diseases were more prevalent among participants aged >40 years. The mean number of medications used was 2.09 and polypharmacy was observed in 10.5% of the study sample. Psychotropic medications were used by a mean of 0.7 individuals of the total sample. The high prevalence of multimorbidity and the common use of multiple medications contributes to a high level of clinical complexity, which appears to be similar to the degree of complexity of the older non-trisomic population. A comprehensive and holistic approach, commonly adopted in geriatric medicine, may provide the most appropriate care to persons with DS as they grow into adulthood.
Identifiants
pubmed: 32449279
doi: 10.1002/ajmg.a.61636
doi:
Substances chimiques
Psychotropic Drugs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1735-1743Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Ballard, C., Mobley, W., Hardy, J., Williams, G., & Corbett, A. (2016). Dementia in Down' s syndrome. The Lancet Neurology, 15(6), 622-636. https://doi.org/10.1016/S1474-4422(16)00063-6
Bittles, A. H., & Glasson, E. J. (2004). Clinical, social, and ethical implications of changing life expectancy in Down syndrome. Developmental Medicine and Child Neurology, 46(4), 282-286.
Calderón-Larrañaga, A., Vetrano, D. L., Onder, G., Gimeno-Feliu, L. A., Coscollar-Santaliestra, C., Carfí, A., … Fratiglioni, L. (2017). Assessing and measuring chronic multimorbidity in the older population: A proposal for its operationalization. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 72(10), 1417-1423. https://doi.org/10.1093/gerona/glw233
Capone, G. T., Chicoine, B., Bulova, P., Stephens, M., Hart, S., Crissman, B., … Smith, D. (2018). Co-occurring medical conditions in adults with Down syndrome: A systematic review toward the development of health care guidelines. American Journal of Medical Genetics, Part A, 176(1), 116-133. https://doi.org/10.1002/ajmg.a.38512
Carfì, A., Bernabei, R., Zampino, G., Onesimo, R., & Onder, G. (2014). Down's syndrome and the paradigm of transition to adult care. Retrieved from http://www.bmj.com/content/349/bmj.g5596/rr/778157
Carfì, A., Brandi, V., Zampino, G., Mari, D., & Onder, G. (2015). Editorial: Care of adults with Down syndrome-Gaps and needs. European Journal of Internal Medicine, 26(6), 375-376. https://doi.org/10.1016/j.ejim.2015.04.018
Carfì, A., Liperoti, R., Fusco, D., Giovannini, S., Brandi, V., Vetrano, D. L., … Onder, G. (2017). Bone mineral density in adults with Down syndrome. Osteoporosis International: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 28(10), 2929-2934. https://doi.org/10.1007/s00198-017-4133-x
Carfì, A., Vetrano, D. L., Mascia, D., Meloni, E., Villani, E. R., Acampora, N., … Onder, G. (2019). Adults with Down syndrome: A comprehensive approach to manage complexity. Journal of Intellectual Disability Research, 63, 1-6. https://doi.org/10.1111/jir.12588
Coppus, A. M. W., Evenhuis, H. M., Verberne, G.-J., Visser, F. E., Oostra, B. A., Eikelenboom, P., … van Duijn, C. M. (2008). Survival in elderly persons with Down syndrome. Journal of the American Geriatrics Society, 56(12), 2311-2316. https://doi.org/10.1111/j.1532-5415.2008.01999.x
Cornacchia, M., Sethness, J., Alapat, P., Lin, Y.-H., & Peacock, C. (2019). The prevalence of OSA among an adult population with Down syndrome referred to a medical clinic. American Journal on Intellectual and Developmental Disabilities, 124(1), 4-10. https://doi.org/10.1352/1944-7558-124.1.4
de Graaf, G., Buckley, F., Dever, J., & Skotko, B. G. (2017). Estimation of live birth and population prevalence of Down syndrome in nine U.S. states. American Journal of Medical Genetics, Part A, 173(10), 2710-2719. https://doi.org/10.1002/ajmg.a.38402
de Graaf, G., Buckley, F., & Skotko, B. G. (2015). Estimates of the live births, natural losses, and elective terminations with Down syndrome in the United States. American Journal of Medical Genetics Part A, 167(4), 756-767. https://doi.org/10.1002/ajmg.a.37001
Dekker, A. D., Sacco, S., Carfi, A., Benejam, B., Vermeiren, Y., Beugelsdijk, G., … de Deyn, P. P. (2018). The behavioral and psychological symptoms of dementia in Down syndrome (BPSD-DS) scale: Comprehensive assessment of psychopathology in Down syndrome. Journal of Alzheimer's Disease, 63(2), 797-820. https://doi.org/10.3233/JAD-170920
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., … Cummings, J. L. (2014). Position paper advancing research diagnostic criteria for Alzheimer' s disease: The IWG-2 criteria. The Lancet Neurology, 13, 614-629. https://doi.org/10.1016/S1474-4422(14)70090-0
Evenhuis, H. M., Hermans, H., Hilgenkamp, T. I. M., Bastiaanse, L. P., & Echteld, M. A. (2012). Frailty and disability in older adults with intellectual disabilities: Results from the healthy ageing and intellectual disability study. Journal of the American Geriatrics Society, 60, 934-938.
Fortea, J., Carmona-Iragui, M., Benejam, B., Fernández, S., Videla, L., Barroeta, I., … Lleó, A. (2018). Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: A cross-sectional study. Lancet Neurology, 17, 860-869.
Giménez, S., Videla, L., Romero, S., Benejam, B., Clos, S., Fernández, S., … Fortea, J. (2018). Prevalence of sleep disorders in adults with Down syndrome: A comparative study of self-reported, actigraphic, and polysomnographic findings. Journal of Clinical Sleep Medicine, 14(10), 1725-1733. https://doi.org/10.5664/jcsm.7382
Glasson, E. J., Dye, D. E., & Bittles, A. H. (2014). The triple challenges associated with age-related comorbidities in Down syndrome. Journal of Intellectual Disability Research, 58(4), 393-398. https://doi.org/10.1111/jir.12026
Haider, S. I., Ansari, Z., Vaughan, L., Matters, H., & Emerson, E. (2014). Prevalence and factors associated with polypharmacy in Victorian adults with intellectual disability. Research in Developmental Disabilities, 35(11), 3071-3080. https://doi.org/10.1016/j.ridd.2014.07.060
Hanney, M., Prasher, V., Williams, N., Jones, E. L., Aarsland, D., Corbett, A., … Ballard, C. (2012). Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): A randomised, double-blind, placebo-controlled trial. Lancet, 379(9815), 528-536. https://doi.org/10.1016/S0140-6736(11)61676-0
Head, E., Silverman, W., Patterson, D., & Lott, I. T. (2012). Aging and Down syndrome. Current Gerontology and Geriatrics Research, 2012, 412536. https://doi.org/10.1155/2012/412536
Jensen, K. M., & Bulova, P. D. (2014). Managing the care of adults with Down's syndrome. British Medical Journal, 349(11), g5596. https://doi.org/10.1136/bmj.g5596
Kerins, G., Petrovic, K., Bruder, M. B., & Gruman, C. (2008). Medical conditions and medication use in adults with Down syndrome: A descriptive analysis. Down's Syndrome, Research and Practice: The Journal of the Sarah Duffen Centre/University of Portsmouth, 12(2), 141-147. https://doi.org/10.3104/reports.2009
Kinnear, D., Morrison, J., Allan, L., Henderson, A., Smiley, E., & Cooper, S. A. (2018). Prevalence of physical conditions and multimorbidity in a cohort of adults with intellectual disabilities with and without Down syndrome: Cross-sectional study. BMJ Open, 8(2), 1-10. https://doi.org/10.1136/bmjopen-2017-018292
Krinsky-McHale, S. J., Silverman, W., Gordon, J., Devenny, D. A., Oley, N., & Abramov, I. (2014). Vision deficits in adults with Down syndrome. Journal of Applied Research in Intellectual Disabilities, 27(3), 247-263. https://doi.org/10.1111/jar.12062
Malt, E. A., Dahl, R. C., Haugsand, T. M., Ulvestad, I. H., Emilsen, N. M., Hansen, B., … Davidsen, E. M. M. (2013). Health and disease in adults with Down syndrome. Tidsskrift for Den Norske Laegeforening: Tidsskrift for Praktisk Medicin, Ny Raekke, 133(3), 290-294. https://doi.org/10.4045/tidsskr.12.0390
Mann, D. M., & Esiri, M. M. (1989). The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. Journal of the Neurological Sciences, 89(2-3), 169-179.
McCarron, M., McCallion, P., Coppus, A., Fortea, J., Stemp, S., Janicki, M., & Wtachman, K. (2018). Supporting advanced dementia in people with Down syndrome and other intellectual disability: Consensus statement of the International Summit on Intellectual Disability and Dementia. Journal of Intellectual Disability Research, 62(7), 617-624. https://doi.org/10.1111/jir.12500
McCarron, M., McCallion, P., Reilly, E., Dunne, P., Carroll, R., & Mulryan, N. (2017). A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome. Journal of Intellectual Disability Research, 61(9), 843-852. https://doi.org/10.1111/jir.12390
McKelvey, K. D., Fowler, T. W., Akel, N. S., Kelsay, J. A., Gaddy, D., Wenger, G. R., & Suva, L. J. (2013). Low bone turnover and low bone density in a cohort of adults with Down syndrome. Osteoporosis International: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 24(4), 1333-1338. https://doi.org/10.1007/s00198-012-2109-4
O'Dwyer, M., Peklar, J., McCallion, P., McCarron, M., & Henman, M. C. (2016). Factors associated with polypharmacy and excessive polypharmacy in older people with intellectual disability differ from the general population: A cross-sectional observational nationwide study. BMJ Open, 6(4), e010505. https://doi.org/10.1136/bmjopen-2015-010505
Picciotti, P. M., Carfì, A., Anzivino, R., Paludetti, G., Conti, G., Brandi, V., … Onder, G. (2017). Audiologic assessment in adults with Down syndrome. American Journal on Intellectual and Developmental Disabilities, 122(4), 333-341. https://doi.org/10.1352/1944-7558-122.4.333
Prasher, V. P. (2015). Down syndrome and thyroid disorders: A review. Down Syndrome Research and Practice, 6(1), 25-42. https://doi.org/10.3104/reviews.95
Real de Asua, D., Quero, M., Moldenhauer, F., & Suarez, C. (2015). Clinical profile and main comorbidities of Spanish adults with Down syndrome. European Journal of Internal Medicine, 26(6), 385-391. https://doi.org/10.1016/j.ejim.2015.05.003
Schoufour, J. D., Mitnitski, A., Rockwood, K., Evenhuis, H. M., & Echteld, M. A. (2015). Predicting 3-year survival in older people with intellectual disabilities using a frailty index. Journal of the American Geriatrics Society, 63, 531-536.
Stoll, C., Dott, B., Alembik, Y., & Roth, M. P. (2015). Associated congenital anomalies among cases with Down syndrome. European Journal of Medical Genetics, 58(12), 674-680. https://doi.org/10.1016/j.ejmg.2015.11.003
Strydom, A., Coppus, A., Blesa, R., Danek, A., Fortea, J., Hardy, J., … Zetterberg, H. (2018). Alzheimer's disease in Down syndrome: An overlooked population for prevention trials. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 4, 703-713. https://doi.org/10.1016/j.trci.2018.10.006